Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CytoMed Therapeutics Limited Ordinary Shares (GDTC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: GDTC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -45.1% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 26.17M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 14784 | Beta - | 52 Weeks Range 1.20 - 4.05 | Updated Date 02/26/2025 |
52 Weeks Range 1.20 - 4.05 | Updated Date 02/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.22 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -735.97% |
Management Effectiveness
Return on Assets (TTM) -17.44% | Return on Equity (TTM) -26.26% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 20656887 | Price to Sales(TTM) 58 |
Enterprise Value 20656887 | Price to Sales(TTM) 58 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -4.45 | Shares Outstanding 11540000 | Shares Floating 3546127 |
Shares Outstanding 11540000 | Shares Floating 3546127 | ||
Percent Insiders 69.27 | Percent Institutions 0.04 |
Analyst Ratings
Rating 5 | Target Price 5 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
CytoMed Therapeutics Limited Ordinary Shares
Company Overview
History and Background
CytoMed Therapeutics Limited is a Singapore-based biotechnology company focused on developing novel cell-based immunotherapies for the treatment of cancers. Founded to address unmet needs in cancer treatment, CytoMed leverages its expertise in T cell biology and genetic engineering to develop innovative therapeutic solutions.
Core Business Areas
- Cell-Based Immunotherapy: Development of cell-based immunotherapies, particularly focusing on engineered T cells, to target and eliminate cancer cells.
- CAR-CIK Technology: Utilizing CAR-CIK (Chimeric Antigen Receptor-Cytokine-Induced Killer) technology to enhance the efficacy and safety of T cell therapies.
- Drug Development: Focuses on research, development, and eventual commercialization of novel therapeutic products designed to combat various types of cancer.
Leadership and Structure
The leadership team comprises experienced professionals in biotechnology, immunology, and oncology. The organizational structure is designed to support research and development, clinical trials, and potential commercialization efforts.
Top Products and Market Share
Key Offerings
- CAR-CIK: CAR-CIK is CytoMed's lead product, a cell-based immunotherapy for treating solid tumors and hematological malignancies. CytoMed is currently undergoing clinical trials for its CAR-CIK product. Competitors include companies developing CAR-T cell therapies, such as Novartis (KIMRIAH), Gilead Sciences (YESCARTA), and Bristol Myers Squibb (BREYANZI), although CytoMed is working on novel approaches that differentiate from these traditional CAR-T therapies.
Market Dynamics
Industry Overview
The cell-based immunotherapy market is experiencing rapid growth, driven by the increasing prevalence of cancer and the limitations of traditional therapies. Advances in genetic engineering and T cell biology are fueling innovation in this field.
Positioning
CytoMed is positioned as an innovator in the cell-based immunotherapy space, particularly with its CAR-CIK technology. Its competitive advantage lies in the potential for improved efficacy and safety compared to existing CAR-T cell therapies.
Total Addressable Market (TAM)
The global cell-based immunotherapy market is projected to reach billions of dollars. CytoMed is targeting specific cancer indications within this large TAM, positioning itself to capture a share of the market through clinical development and commercialization of its therapies.
Upturn SWOT Analysis
Strengths
- Novel CAR-CIK technology
- Strong expertise in T cell biology
- Experienced leadership team
- Focus on unmet needs in cancer treatment
Weaknesses
- Early-stage development
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on clinical trial success
- Concentration of product pipeline
Opportunities
- Expanding clinical trials to new cancer indications
- Partnerships with larger pharmaceutical companies
- Securing regulatory approvals for its therapies
- Advancements in manufacturing and delivery technologies
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- NVS
- GILD
- BMY
Competitive Landscape
CytoMed faces competition from established pharmaceutical companies developing CAR-T cell therapies, as well as other emerging biotechnology companies in the cell-based immunotherapy space. CytoMed's CAR-CIK technology offers potential advantages in terms of efficacy and safety, but clinical trial success is critical for competitive differentiation.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by advancements in its CAR-CIK technology and progress through clinical trials.
Future Projections: Future growth is dependent on clinical trial success, regulatory approvals, and commercialization of its therapies. Analyst estimates depend on trial outcomes and market adoption.
Recent Initiatives: Recent initiatives include expanding clinical trials for CAR-CIK and securing partnerships to advance its research and development programs.
Summary
CytoMed Therapeutics is an early-stage biotechnology company with a promising CAR-CIK technology for cancer immunotherapy. Its success hinges on positive clinical trial outcomes and the ability to secure regulatory approvals. Competition is intense, but the company's novel approach provides a potential competitive advantage. Financial stability is critical for sustaining research and development efforts.
Similar Companies
- NVS
- GILD
- BMY
- CRSP
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CytoMed Therapeutics Limited Ordinary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-04-14 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://w2.cytomed.sg |
Full time employees - | Website https://w2.cytomed.sg | ||
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company also has Business & Research Collaboration Agreement with SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.